How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

260 results for

Adamantane

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

21. N′-(Adamantan-2-yl­idene)benzo­hydrazide Full Text available with Trip Pro

N′-(Adamantan-2-yl­idene)benzo­hydrazide The title mol-ecule, C(17)H(20)N(2)O, is a functionalized hydrazine with benzoyl and adamantyl substituents attached to the two hydrazine N atoms. In the crystal, mol-ecules are linked via N-H⋯N hydrogen bonds, forming chains propagating along the a-axis direction. There are also C-H⋯O, C-H⋯N and C-H⋯π inter-actions present within the chains.

2012 Acta Crystallographica Section E: Structure Reports Online

22. 5-(Adamantan-1-yl)-3-[(2-meth­oxy­eth­yl)sulfan­yl]-4-phenyl-4H-1,2,4-triazole Full Text available with Trip Pro

5-(Adamantan-1-yl)-3-[(2-meth­oxy­eth­yl)sulfan­yl]-4-phenyl-4H-1,2,4-triazole In the title adamantyl derivative, C(21)H(27)N(3)OS, the terminal meth-oxy-ethyl unit is disordered over two orientations with a refined site-occupancy ratio of 0.846 (6):0.154 (6). The 1,2,4-triazole ring is statistically planar [r.m.s. deviation = 0.002 (2) Å] and the phenyl substituent is almost perpendicular to its mean plane [dihedral angle = 83.57 (11)°]. No directional inter-molecular inter-actions were

2012 Acta Crystallographica Section E: Structure Reports Online

23. catena-Poly[[[aqua­(1,10-phenanthro­line)manganese(II)]-μ-adamantane-1,3-dicarboxyl­ato] monohydrate] Full Text available with Trip Pro

catena-Poly[[[aqua­(1,10-phenanthro­line)manganese(II)]-μ-adamantane-1,3-dicarboxyl­ato] monohydrate] In the title coordination polymer, {[Mn(C(12)H(14)O(4))(C(12)H(8)N(2))(H(2)O)]·H(2)O}(n), the Mn(II) atom has a highly distorted cis-MnN(2)O(4) octa-hedral geometry arising from its coordination by a bidentate phenanthroline ligand, a water mol-ecule and monodentate and bidentate adamantane-1,3-dicarboxyl-ate dianions. The bridging dianion leads to [001] chains in the crystal. The chains

2011 Acta Crystallographica Section E: Structure Reports Online

24. Bis(μ-adamantane-1,3-dicarboxyl­ato-κ4 O 1,O 1′:O 3,O 3′)bis­[aqua­(3-carboxy­adam­antane-1-carboxyl­ato-κO 1)(1,10-phen­an­throline-κ2 N,N′)erbium(III)] dihydrate Full Text available with Trip Pro

Bis(μ-adamantane-1,3-dicarboxyl­ato-κ4 O 1,O 1′:O 3,O 3′)bis­[aqua­(3-carboxy­adam­antane-1-carboxyl­ato-κO 1)(1,10-phen­an­throline-κ2 N,N′)erbium(III)] dihydrate The asymmetric unit of the binuclear centrosymmetric title compound, [Er(2)(C(12)H(14)O(4))(2)(C(12)H(15)O(4))(2)(C(12)H(8)N(2))(2)(H(2)O)(2)]·2H(2)O, contains one Er(III) atom, one coordinated water mol-ecule, one 1,10-phenanthroline (phen) ligand, two differently coordinated adamantane-1,3-dicarboxyl-ate (H(2)L

2011 Acta Crystallographica Section E: Structure Reports Online

25. (2SR,3RS)-Methyl 2-(adamantan-1-yl)-3-phenyl­sulfonyl-3-(pyridin-2-ylsulfan­yl)propano­ate dichloro­methane hemisolvate Full Text available with Trip Pro

(2SR,3RS)-Methyl 2-(adamantan-1-yl)-3-phenyl­sulfonyl-3-(pyridin-2-ylsulfan­yl)propano­ate dichloro­methane hemisolvate The title compound, C(25)H(29)NO(4)S(2) 0.5CH(2)Cl(2), was obtained as a racemate. The pyridine and phenyl rings are arranged face-to-face, giving a weak intra-molecular π-π inter-action [centroid-centroid separation = 3.759 (3) Å]. These inter-actions are extended inter-molecularly, forming chains of stacked rings along [001] with separations of 3.859 (3) and 3.916 (3) Å

2011 Acta Crystallographica Section E: Structure Reports Online

26. Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. Full Text available with Trip Pro

Dual resistance to adamantanes and oseltamivir among seasonal influenza A(H1N1) viruses: 2008-2010. Two distinct genetic clades of seasonal influenza A(H1N1) viruses have cocirculated in the recent seasons: clade 2B oseltamivir-resistant and adamantane-susceptible viruses, and clade 2C viruses that are resistant to adamantanes and susceptible to oseltamivir. We tested seasonal influenza A(H1N1) viruses collected in 2008-2010 from the United States and globally for resistance to antivirals (...) approved by the Food and Drug Administration. We report 28 viruses with both adamantane and oseltamivir (dual) resistance from 5 countries belonging to 4 distinct genotypes. Because of limited options for antiviral treatment, emergence of dual-resistant influenza viruses poses a public health concern, and their circulation needs to be closely monitored.

2011 Journal of Infectious Diseases

27. Peramivir (Alpivab) - Influenza, Human

. There are no licensed intravenous presentations of neuraminidase inhibitors in the EU although these may be available for compassionate use in severely ill patients, in whom their efficacy has not been established. Otherwise, treatment for severe influenza is supportive and may involve the need for assisted ventilation, circulatory support and antibacterial agents to treat or prevent secondary bacterial infections, such as staphylococcal pneumonia. In some countries amantadine and rimantadine (the adamantanes

2018 European Medicines Agency - EPARs

29. 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza Full Text available with Trip Pro

as an alternative to antiviral chemoprophylaxis (C-III) . XI. Which antiviral drugs should be used for preexposure chemoprophylaxis for influenza? Clinicians should use an NAI (oral oseltamivir or inhaled zanamivir) if preexposure chemoprophylaxis for influenza is administered rather than an adamantane antiviral (A-II) . XII. What is the duration of preexposure antiviral chemoprophylaxis to prevent influenza? Clinicians should administer preexposure antiviral chemoprophylaxis for adults and children aged ≥3 (...) to antiviral treatment dosing in persons receiving postexposure antiviral chemoprophylaxis who become symptomatic, preferably with an antiviral drug with a different resistance profile if not contraindicated (A-III) . XVI. Which antiviral drugs should be used for postexposure chemoprophylaxis? Clinicians should administer an NAI (inhaled zanamivir or oral oseltamivir) if postexposure chemoprophylaxis for influenza is given, rather than an adamantane antiviral (A-II) . Institutional Outbreak Control XVII

2019 Infectious Diseases Society of America

30. [Saxagliptin/metformin (type 2 diabetes) - benefit assessment according to õ35a Social Code Book V]

(type 2 diabetes) - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 554. 2017 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Humans; Metformin; saxagliptin Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im

2018 Health Technology Assessment (HTA) Database.

31. Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008) Full Text available with Trip Pro

Adamantane resistance in seasonal human influenza A viruses from Calgary, Alberta (January 2007 to August 2008) The available antivirals for the treatment and prophylaxis of influenza A infections include the adamantanes (amantadine and rimantadine), which are matrix (M2) protein inhibitors, and the neuraminidase inhibitors (oseltamivir and zanamivir). Resistance to the adamantanes is conferred by mutations at amino acid positions 26, 27, 30, 31 or 34 within the M2 protein of influenza (...) A viruses. A significant increase in adamantane resistance has been reported worldwide since 2003, reflected by a similar increase in Canada. The present study reports on the frequency of adamantane resistance in seasonal influenza A viruses in Calgary, Alberta, for the period between January 2007 and August 2008, as an update to the previous report. Positive influenza A samples (221 original patient specimens and 34 isolates obtained by viral culture) were analyzed for changes in the critical amino

2010 The Canadian Journal of Infectious Diseases & Medical Microbiology

32. 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia Full Text available with Trip Pro

1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea (AR9281) as a potent, selective, and orally available soluble epoxide hydrolase inhibitor with efficacy in rodent models of hypertension and dysglycemia 1-(1-Acetyl-piperidin-4-yl)-3-adamantan-1-yl-urea 14a (AR9281), a potent and selective soluble epoxide hydrolase inhibitor, was recently tested in a phase 2a clinical setting for its effectiveness in reducing blood pressure and improving insulin resistance in pre-diabetic patients. In a mouse

2010 Bioorganic & medicinal chemistry letters

33. A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009. Full Text available with Trip Pro

A comprehensive surveillance of adamantane resistance among human influenza A virus isolated from mainland China between 1956 and 2009. Adamantane-derived drugs have been used for treatment and prophylaxis of influenza A virus infection for many years worldwide. Rapid surveillance of antiviral drug resistance is important for appropriate clinical guideline development. Here, we retrospectively assessed adamantane resistance among different influenza A subtypes (H1N1, H3N2 and H5N1) over 53 (...) years (1956-2009) in mainland China.A total of 1,451 viruses, including 773 H3N2 viruses, 647 H1N1 viruses and 31 human H5N1 viruses, were analysed by matrix gene sequencing and assayed for drug resistance.Our results show that the prevalence of adamantane-resistant H3N2 viruses was low between 1956 and 2002, but substantially increased in 2003 to the extent that since 2006 all H3N2 viruses have been drug resistant. The percentage of adamantane-resistant H1N1 viruses also increased from 50.0

2010 Antiviral Therapy

34. [Saxagliptin / metformin - benefit assessment according to õ 35a Social Code Book V]

; Auftrag A16-4. [Saxagliptin / metformin - benefit assessment according to § 35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 44. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Dipeptides; Germany; Humans; Metformin; State Medicine Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG

2017 Health Technology Assessment (HTA) Database.

35. [Saxagliptin - benefit assessment according to õ35a Social Code Book V]

Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 442. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Dipeptides; Humans Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685 - 1 Email: berichte

2017 Health Technology Assessment (HTA) Database.

36. CRACKCast E130 – Viruses

by inhibiting the release of viral progeny from infected cells. These drugs are active against both influenza A and B. Amantadine and rimantadine are the currently available adamantane antivirals. – they are NOT recommended because influenza strains are 90% resistant to them . Start them ASAP ( don ’ t wait for testing ) – ideally within 48 hrs of onset . From Uptodate : “ Adults with mild illness without high – risk conditions who are younger than 65 years of age do not require testing or treatment

2017 CandiEM

37. Molecular characterization of influenza A(H1N1)pdm09 in Cameroon during the 2014-2016 influenza seasons. Full Text available with Trip Pro

(HA, NA and M) of Cameroon strains were studied. The phylogenetic tree of the coding nucleotide sequences was generated by MEGA version 6.0 using a Maximum Likelihood method. The NA and M protein coding sequences were analyzed for the reported genetic markers of resistance against neuraminidase inhibitors and adamantanes, while predicted vaccine efficacy was estimated using the Pepitope method. Overall 39 strains were obtained. Phylogenetic analysis of the HA gene of influenza A(H1N1)pdm09 showed

2019 PLoS ONE

38. Saxagliptin + saxagliptin/metformin: Addendum to Commission A16-42 + A16-43

to Commission A16-42 + A16-43] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 464. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adamantane; Dipeptides; Humans; Metformin Language Published German Country of organisation Germany English summary There is no English language summary available. Address for correspondence IQWiG, Im Mediapark 8, DE-50670 Cologne, GERMANY, Tel: +49 (0) 221 - 35685 - 0, Fax: +49 (0) 221 - 35685

2016 Health Technology Assessment (HTA) Database.

39. Ebilfumin - oseltamivir

. The most effective way to prevent the disease or severe outcomes from the illness is vaccination. In addition, antiviral drugs for treatment and prevention of influenza are available. There are two classes of such medicines, 1) adamantanes (amantadine and remantadine), and 2) inhibitors of influenza neuraminidase (oseltamivir and zanamivir). Ebilfumin (oseltamivir), a neuraminidase inhibitor, ATC Code: J05AH02, is a generic of the originator product Tamiflu. The active metabolite is a selective

2014 European Medicines Agency - EPARs

40. Peramivir (Rapivab)

in previously healthy adults. Zanamivir and oseltamivir are active against both influenza A and B viruses, but differ in pharmacokinetics, safety profiles, route of administration, approved age groups, and recommended dosages. Zanamivir is administered through oral inhalation by using a plastic device included in the medication package. Oseltamivir is available for oral administration in 30 mg, 45 mg, and 75 mg capsules and liquid suspension. The adamantanes are the other class of approved influenza (...) antiviral agents and include amantadine and rimantadine. Adamantanes are thought to interact with the viral M2 ion channel protein. When administered within 48 hours of illness onset, amantadine and rimantadine can reduce the severity and shorten the duration of acute uncomplicated influenza A illness among healthy adults; however, they have no activity against influenza B virus. In recent years, widespread adamantane resistance among influenza A virus strains (H3N2, H1N1pdm09) has made this class

2014 FDA - Drug Approval Package

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>